Equities researchers at Canaccord Genuity assumed coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at RBC Capital initiated coverage on shares of Aerie Pharmaceuticals in a research note to investors on Tuesday. They set an “outperform” rating and a $20.00 price target on the stock. Analysts at Stifel Nicolaus initiated coverage on shares of Aerie Pharmaceuticals in a research note to investors on Tuesday. They set a “buy” rating and a $18.00 price target on the stock.
Aerie Pharmaceuticals (NASDAQ:AERI) opened at 10.61 on Tuesday. The stock’s 50-day moving average is $0. and its 200-day moving average is $0.. The company’s market cap is $235.6 million.
Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.